Jabil Inc. and Kymanox Corporation have entered into a non-exclusive collaboration to support companies developing and commercialising drug-device combination products and other complex life science innovations.
Companies with cutting-edge pharmaceutical or device technologies may lack the in-house expertise to navigate the next steps of drug development.
These include lengthy and expensive regulatory pathways, comprehensive testing, complex manufacturing and supply chain management.
Jabil and Kymanox can bridge that gap through their combined capabilities across the full product lifecycle.
“With the acquisition of Pharmaceutics International, Inc. (Pii) in February, Jabil established itself in the CDMO realm, adding new drug product development and sterile fill-finish capabilities to our portfolio."
"Our collaboration with Kymanox takes this a step further — enabling us to offer pharmaceutical customers early stage support with regulatory strategy and development to complement Jabil’s existing regulatory, development, commercialisation, manufacturing and packaging services,” said Mike Mahaz, SVP, Global Business Units, Healthcare, at Jabil.
"Jabil and Kymanox can help pharma and biotech innovators manage complexity, accelerate timelines, and deliver life-changing therapies to patients worldwide.”
“This collaboration allows us to leverage Kymanox’s deep technical and regulatory expertise with Jabil’s drug and device development, industrialisation, and world-class manufacturing capabilities,” said Nicholas Ciccarelli, Chief Technology Officer at Kymanox.
“Together, we can help clients move more efficiently from pre-clinical to commercial — ensuring that promising therapies reach patients faster.”